Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
I bought glove before the pandemic strike and now I bought Genting & Genm before the business recover. I buy in advance and I get cheap entry. If I buy when the business is recovering than the entry price would be way too high. That's my strategy of investment.
参考：你可以google这篇11月12号的报道 最近美方的报道都围绕这个主题：Stock market news live updates: Stocks extend declines as vaccine rally cools further, daily COVID-19 cases hit record
Stocks fell Thursday, with the Dow and S&P 500 adding to Wednesday’s losses, as optimism over a COVID-19 vaccine gave way to fear that rising coronavirus infections will derail a still evolving recovery.
[Click here to read what’s moving markets heading into Friday, Nov. 13]
The pandemic has tightened its grip on the world’s largest economy, with new COVID-19 cases hitting a record of more than152,000 on Wednesday alone, according to data from Johns Hopkins University and Bloomberg. Meanwhile, hospitalizations are surging and death rates are also on the rise.
Concerns over prospects for a stimulus bill out of Washington also spooked investors. Bloomberg reported Thursday that the Trump administration was pulling back on negotiating the details of a new spending package — leaving the onus of working out a deal to congressional lawmakers including Senate Majority Leader Mitch McConnell and House Speaker Nancy Pelosi.
Despite being carried by a wave of optimism over a potential vaccine — which sparked a powerful rally earlier in the week — the convergence of bad news sent major benchmarks tumbling into the close.
The Nasdaq outperformed but was still lower intraday, after rising 2% on Wednesday as the index tried to make up some steep losses from earlier this week. Earlier, investors fled high-growth tech shares, and piled into value and cyclical stocks on hopes that a vaccine would drive a faster economic recovery and lift businesses hardest hit earlier during the pandemic.
That swift rotation, however, was likely overdone, according to some analysts.
“I would say the death of tech was excessively premature,” Brian Belski, BMO Capital Markets chief investment strategist, told Yahoo Finance.
“Coming out of a recession and really kind of questioning what growth is going to look like over the next couple of quarters, and the higher likelihood of additional lockdowns on a state or even nation-wide level, really puts that increased confidence and bid in the technology stocks,” he added. “So again, the death of technology stocks and the stay-at-home trade I think is way, way, way too early.”
The U.S. has recently faced an increasingly dire situation with COVID-19, with the number of new cases reported daily topping 100,000 each day since Nov. 4, according to data compiled by the New York Times.
The rising infection rate threatens to put the brakes on the economic recovery despite improving prospects for a vaccine, given that approval and distribution likely won’t come for another at least several more months. Pfizer (PFE) earlier this week reported early efficacy data showing their vaccine candidate was more than 90% effective in preventing COVID-19, and Moderna (MRNA) said it was closing in on releasing data from its own late-stage clinical trial in the near-term.
“The virus resurgence poses a key risk to the growth outlook,” Goldman Sachs economist Jan Hatzius said in a note Wednesday, warning that new lockdowns would jeopardize growth that’s still rebounding from the restrictions seen in the spring.
“While the data also suggest that voluntary consumer behavior has responded less strongly to increased virus risks during the recent resurgence, this could change should perceived risks increase as case counts, hospitalizations, and fatalities rise,” Hatzius added.
Separately, investors digested new labor market data that, while better than expected, failed to improve market psychology. Another 709,000 Americans filed for first-time unemployment benefits last week, for a level still more than three times higher than the weekly average of new claims in 2019. And more than 21 million Americans remain on unemployment benefits of some form.
No, why do I want to create panic? I speak calmly, did I say sell all sell all run run run?
I specifically say I am not advising to sell, and remind to be careful as prospect is uncertain - did genting suddenly become super profitable?
Sure I have been investing in Topglvoe for years, but that did not take away anything from me to appreciate Genting. In fact, I never praise Topglvoe and say buy buy buy go go go. I always discuss about pros and cons, not just gogogogoggogogog
I'm holding TOPGLOV too but I don't advice to buy. Still waiting to dispose at a breakeven price. Upside are very limited as the recent trading pattern can tell. Company director are buying back shares to support the price but for how long can this be sustain?